Inito Closes $29M Series B Round for At-Home Health

Inito has secured $29,000,000 in a recent funding round, marking a significant milestone for the at-home healthcare innovator.

The company is dedicated to shaping the future of accessible biological data, enabling more individuals to understand their health from home.

Inito's flagship product is an FDA-registered fertility monitor that precisely measures four key fertility hormones using a single test strip, providing results in just 10 minutes.

This substantial capital infusion will support Inito's ongoing mission to expand its impact in the at-home diagnostics sector.

The company has already established a strong presence, trusted by over 75,000 couples and recognized as a leading fertility tracker.

Through its platform, users have conducted over 5 million tests, generating more than 15 million data points that are contributing to a deeper understanding of fertility.

The $29,000,000 investment is earmarked for accelerating growth initiatives.

These plans include intensifying research and development efforts to broaden Inito's product offerings beyond fertility, as well as scaling its operational infrastructure.

Inito operates with a diverse team of over 100 engineers across hardware, software, and biosciences, based in Houston, Bangalore, and Dubai, all working towards enhancing at-home healthcare solutions.

This funding round underscores investor confidence in Inito's vision to democratize access to lab-grade health data.

The company aims to leverage this capital to further its goal of turning complex biological information into practical, everyday insights for improved health management.

Inito anticipates that this investment will significantly bolster its capacity to close critical gaps in at-home healthcare and deliver on its mission to empower individuals with better health understanding from the inside out.